sorafenib has been researched along with Fever in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M | 1 |
Chen, X; Cui, T; Diao, X; Huang, S; Sun, J | 1 |
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I | 1 |
Fujimoto, K; Gemma, A; Horiuchi-Yamamoto, Y; Inoue, Y; Johkoh, T; Kudoh, S; Sakai, F; Taniguchi, H | 1 |
4 other study(ies) available for sorafenib and Fever
Article | Year |
---|---|
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Dermatitis; Diarrhea; Fatigue; Female; Fever; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2014 |
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Sorafenib; Treatment Outcome | 2016 |
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Fever; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Humans; Japan; Liver Neoplasms; Lung; Male; Marketing; Middle Aged; Niacinamide; Phenylurea Compounds; Pulmonary Alveoli; Sorafenib | 2013 |